Car-T Cells for Research

ProMab Biotechnologies offers a variety of CAR-T cells. These are activated human T cells expressing chimeric antigen receptors specific for a variety of target antigens, many of which are overexpressed on tumor cells. These target antigens include CD19, BCMA, Her-2, EGFR, Mesothelin, and more (see Table, below). The CARs are modified in a number of ways, including using different costimulatory domains to alter functional responses or incorporating non-immunogenic tags for CAR identification and selection. Some of our CAR-T cells express additional proteins from a separate promoter, like GFP or truncated EGFR.

ProMab’s CAR-T cells are generated from healthy donors using high-titer, replication-defective lentivirus. The CAR-T cells are validated using multiple methods, including flow cytometry (to determine CAR-T frequency, phenotype, and checkpoint protein levels), real-time and end-point cytotoxicity assays, and ELISA to measure target antigen-induced cytokine production.

Because T cells themselves can react with tumor cells, ProMab suggests using activated T cells (PM-CAR2003) as a negative control alongside our CAR-T cells to evaluate CAR-dependent versus CAR-independent effects. Mock CAR-T cells (PM-CAR1061, PM-CAR1086) serve as an additional control, as they contain a CAR – like the CAR-T cells – but do not possess an antigen-binding domain.